Original Source(s)
Related Content
FDA expands talazoparib use in prostate cancer
The combination with enzalutamide reduced the risk of radiographic progression or death by 52% .
by Mouj Hijazi
October 27, 2026
-
3 min
FDA expands bladder cancer therapy approval
The expansion offers another treatment option for patients with high-grade tumors following BCG failure.
by Mouj Hijazi
October 14, 2026
-
3 min
Endometrial cancer drug cuts progression or death risk 41%
FDA grants Priority Review following improved survival versus chemotherapy in phase 3 trial.
by Mouj Hijazi
October 27, 2026
-
3 min